Fareeha Mubin
Nephrology · Philadelphia, PANPI 1548825904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $885 and has fallen 58.7% since, to $365 in 2025.
Across 95 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$317
- AstraZeneca$245
- Novartis$240
- Mallinckrodt Hospital Products Inc.$166
- ANI Pharmaceuticals, Inc.$156
- Vifor Pharma, Inc.$154
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,338100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 11 | $317 |
| AstraZeneca | 12 | $245 |
| Novartis | 11 | $240 |
| Mallinckrodt Hospital Products Inc. | 2 | $166 |
| ANI Pharmaceuticals, Inc. | 7 | $156 |
| Vifor Pharma, Inc. | 8 | $154 |
| Aurinia Pharma U.S., Inc. | 8 | $152 |
| Amgen | 6 | $147 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Ardelyx, Inc. | 3 | $109 |
| GSK | 4 | $80 |
| Akebia Therapeutics Inc | 3 | $66 |
| Travere Therapeutics, Inc. | 4 | $57 |
| Calliditas Therapeutics US Inc. | 1 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Leadiant Biosciences, Inc. | 2 | $38 |
| Fresenius USA Marketing, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Sanofi | 1 | $32 |
| Merck | 1 | $32 |
| Veloxis Pharmaceuticals, Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $16 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$145
- THYMOGLOBULIN$121
How this compares
$2,338 in reported general payments places this provider in the 75th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Katalin SusztakPhiladelphia$192K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Michael LevinPhiladelphia$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.